-
-
-
-
-
-
-
Aligos licenses hepatitis B drug to Amoytop for $25M upfront
-
-
-
-
-
-
-
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
-
-
-
-
-
-
-
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Aligos Therapeutics to Present at Investor Conferences in December
-
-
-
-
-
-
-
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MAS
-
1,198,973 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

